To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Age between 18 and 80 years old, and expected survival is longer than 3 months
Clinically or pathologically diagnosed as primary hepatocellular carcinoma
Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment
Child-Pugh score of liver function A/B (< 7)
Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon
Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation
Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10^4 before receiving treatment or do not continue to take antiviral drugs regularly
Pregnant patients
Single group
Cryoablation
Procedure/SurgeryAfter the completion of screening, the subjects received cryoablation treatment
PD-1 antibody and bevacizumab
DrugThree days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
Progression-free survival
mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit.
Time to progress
mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit.
Objective Response Rate
mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit.
Overall survival
According to medical documents or descriptions of the patient's family
Adverse events
CTCAE v5.0 is used to assess adverse events.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
